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Abstract
Overwhelming evidence from leukemia research has shown that the clonal population of neoplastic cells exhibits
marked heterogeneity with respect to proliferation and differentiation. There are rare stem cells within the
leukemic population that possess extensive proliferation and self-renewal capacity not found in the majority of the
leukemic cells. These leukemic stem cells are necessary and sufficient to maintain the leukemia. While the
hematopoietic stem cell (HSC) origin of CML was first suggested over 30 years ago, recently CML-initiating cells
beyond HSCs are also being investigated. We have previously isolated fetal liver kinase-1-positive (Flk1
+) cells
carrying the BCR/ABL fusion gene from the bone marrow of Philadelphia chromosome-positive (Ph
+) patients with
hemangioblast property. Here, we showed that CML patient-derived Flk1
+CD31
-CD34
-MSCs had normal
morphology, phenotype and karyotype but appeared impaired in immuno-modulatory function. The capacity of
patient Flk1
+CD31
-CD34
- MSCs to inhibit T lymphocyte activation and proliferation was impaired in vitro. CML
patient-derived MSCs have impaired immuno-modulatory functions, suggesting that the dysregulation of
hematopoiesis and immune response may originate from MSCs rather than HSCs. MSCs might be a potential
target for developing efficacious cures for CML.
Introduction
Chronic Myeloid Leukemia(CML) is a malignant myelo-
proliferative disorder originating from a pluripotent
stem cell that expresses the BCR/ABL oncogene and is
characterized by abnormal release of the expanded,
malignant stem cell clone from the bone marrow into
the circulation[1,2]. The discovery of the Philadelphia
chromosome followed by identification of its BCR/ABL
fusion gene product and the resultant constitutively
active P210 BCR/ABL tyrosine kinase prompted the
unravelling of the molecular pathogenesis of CML.
However, regardless of greatly reduced mortality rates
with BCR/ABL targeted therapy, most patients harbor
quiescent CML stem cells that may be a reservoir for
disease progression to blast crisis. Under steady-state
conditions, these cancer stem cells are localized in a
microenvironment known as the stem cell “niche”,
where they are maintained in an undifferentiated and
quiescent state. These niches are critical for regulating
the self-renewal and cell fate decisions, yet why and
how these cells are recruited to affect leukemia progres-
sion are not well known.
Local secretion of proteases has been implicated in
this tumor-stroma crosstalk. Matrix metalloproteinase-9
(MMP-9) is one of the proteases that has the preferen-
tial ability to degrade denatured collagens (gelatin) and
collagen type IV, the 2 main components of basement
membranes and therefore plays a critical role in tumor
progression and metastasis[3,4]. Previous studies have
demonstrated localization of MMP-9 on the plasma
membrane of various tumor cells[5-7] and recently, the
role of MMP-9 in CML pathogenesis has became a
focus of attention[8-11]. But the research is mainly
focusing on the MMP-9 inducing molecules[12-14] or
the effect of MMP-9 inhibitors[15]. However, it has
become clear that the role of MMP-9 in CML is not
limited to simple extracellular matrix (ECM) degrada-
tion[16]. The regulation of MMP-9 is found to be
involved in multiple pathways induced by different kinds
of cytokines in different cell types and illness[17,18].
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Recent research[6,10,4] showed that T lymphocytes
isolated from CML patients suppressed the forming of
CFU-GM (colony forming unit-granulocyte and macro-
phage) and CFU-E (colony forming unit-erythroid) and
furthermore this kind of inhibition could be blocked by
CsA(cyclosporine A)[19,20];besides, the rate of the
forming of the HSCs (hematopoietic stem cells)
increased with the removal of T lymphocytes. Therefore,
immunological inhibitors like CsA. and ATG (anti-
human thymocyte globulin) was helpful for CML
patients and was widely used in clinic therapy[21-23].
All these evidence indicated there might existed immu-
nological abnormalities, that is, the T lymphocytes in
CML might existed in a unusually activated state leading
to self injury.
Besides HSCs, there also existed another kind of stem
cells called MSCs (Mesenchymal Stem Cells), they could
differentiated into stroma cells and acted as the “niche”
in the micro-environment[24]. MSCs also had the
immunological regulation ability and were believed to
be the “immune protection site” in the cells environ-
ment. So, we believed that MSCs might play important
role in the pathogenesis of CML, but there was no arti-
cle examined the immunological function of MSCs.
Previous studies[19,21] from our laboratory have iden-
tified Flk1
+( fetal liver kinase-1 positive) CD31
-CD34
-
cells carrying the BCR/ABL fusion gene from the bone
marrow of Philadelphia chromosome positive (Ph
+)
patients with CML and found that these cells could dif-
ferentiate into malignant blood cells and phenotypically
defined endothelial cells at the single-cell level, suggest-
ing these cells have the properties of hemangioblasts.
The main purpose of our article was to examine the
immune characteristics of Flk1
+CD31
-CD34
- MSC in
CML and analyse if there existed abnormalities compar-
ing with the healthy donors.
Patients, materials, and methods
Patient samples
20 patients with newly diagnosed CML (12 male and 8
female, aged 17-63 years) were recruited in this study
(table 1). All were Ph
+ patients with CML in chronic
phase as revealed by bone marrow histology and cytoge-
netic analysis. The immunophenotypes of thawed cells
were quite variable. None was treated with hydroxyurea
or interferon before. The control samples were from 20
healthy donors (12 male and 8 female, aged 21-60
years). Bone marrow samples were collected after
obtaining informed consent according to procedures
approved by the Ethics Committee at the 309
th Hospital
of Peoples Liberation Army.
Cell preparations and culture
Isolation and culture of bone marrow-derived CML
hemangioblasts were performed as described previously
with some modifications[19,21]. Briefly, mononuclear
cells were separated by a Ficoll-Paque gradient centrifu-
gation (specific gravity 1.077 g/mL; Nycomed Pharma
AS, Oslo, Norway) and the sorted cells were plated at
concentration of 1 cell/well by limiting dilution in a
total of 96 × 10 wells coated with fibronectin (Sigma, St
Louis, MO) and collagen (Sigma) for each patient. Cul-
ture medium was Dulbecco modified Eagle medium and
Ham F12 medium (DF12) containing 40% MCDB-201
medium complete with trace elements (MCDB) (Sigma),
2% fetal calf serum (FCS; Gibco Life Technologies,
Table 1 The general conditions of the patients
Patient Age Sex Diagonosis Diagnosis time Ph chromosome Immunosuppressive therapy
1 84 F CML Aug-04 positive yes
2 54 M CML Jun-87 positive yes
3 56 M CML May-99 positive yes
4 49 M CML Feb-87 positive yes
5 66 M CML Aug-04 positive yes
6 40 F CML Feb-05 positive No
7 50 F CML Sep-04 positive No
8 76 F CML Aug-04 positive No
9 64 F CML Dec-05 positive No
10 55 M CML Apr-00 positive yes
11 49 M CML Feb-05 positive No
12 51 M CML Jun-01 positive yes
13 40 F CML Dec-05 positive No
14 43 F CML Dec-05 positive No
15 60 M CML Nov-05 positive No
M: male; F:female;
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nium (Gibco Life Technologies), 10
-9 M dexamethasone
(Sigma), 10
-4 M ascorbic acid 2-phosphate (Sigma), 20
ng/mL interleukin-6 (Sigma), 10 ng/mL epidermal
growth factor (Sigma), 10 ng/mL platelet-derived growth
factor BB (Sigma), 50 ng/mL fetal liver tyrosine kinase 3
(Flt-3) ligand (Sigma), 30 ng/mL bone morphogenetic
protein-4 (Sigma), 100 U/mL penicillin and 100 ug/mL
streptomycin (Gibco Life Technologies) at 37°C and a
5% CO2 humidified atmosphere. Culture media were
changed every 4 to 6 days.
FISH analysis
We cultured BCR/ABL
+ hemangioblasts from male CML
patients (n = 12) and Y chromosome was detected using a
probe (CEP Y Spectrum Red; Vysis, Downers Grove, IL)
according to the manufacturer’s instructions. Normal cells
showed 2 red abl signals and 2 green bcr signals. BCR/
ABL
+ hemangioblasts showed a single red and a single
green signal representing normal abl and bcr genes and
the yellow signal representing fusion of abl and bcr genes.
Fluorescence activated cell sorting (FACS)
For immunophenotype analysis, expanded clonal cells
were stained with antibodies against Flk1, CD29, CD31,
CD34, CD44, CD45, CD105, (all from Becton Dickinson
Immunocytometry Systems, Mountain View, CA). For
intracellular antigen detection, cells were first fixed in 2%
paraformaldehyde (Sigma) for 15 minutes at 4°C and per-
meabilized with 0.1% saponin (Sigma) for 1 hour at room
temperature. Cells were washed and labeled with fluores-
cein isothiocyanate (FITC) conjugated secondary goat
antimouse, goat antirabbit, or sheep antigoat antibodies
(Sigma), then washed and analyzed using a FACS Calibur
flow cytometer (Becton Dickinson, San Jose, CA).
Mitogen proliferative assays
Inmitogen proliferative assays, triplicate wells containing
responder 1 × 105 MNCs were cultured with 50 g/ml
PHA (Roche, USA) in a total volume of 0.1 ml medium
at 37°C in 5% CO2, and Flk1+CD31-CD34- MSCs were
added on day 0. Irradiated Flk1+CD31-CD34- MSCs (30
Gy) were cocultured with the MNCs at different ratios
(MSCs to MNCs = 1:2, 1:10, 1:100). Control wells con-
tained only MNCs. Cultures were pulsed with 1 Ci/well
[3H]-TdR (Shanghai Nucleus Research Institute, China)
on day 2, and harvested 18 h laterwith a Tomtec (Wal-
lac Inc., Gaithersburg, MD) automated harvester. Thy-
midine uptake was quantified using a liquid scintillation
and luminescence counter (Wallac TRILUX).
Mixed lymphocyte reaction assays (MLR)
Blood mononuclear cells (MNCs) were prepared from
normal volunteers’ peripheral blood by Ficoll-Paque
density gradient centrifugation and suspended inRPMI
1640 medium supplemented with 10% (vol/vol) FCS, 2
mM l-glutamine,0.1 mM nonessential amino acids (Life
T e c h n o l o g i e s ,G r a n dI s l a n d ,N Y ) ,1m Ms o d i u mp y r u -
vate, 100 U/mL penicillin,
Effect of MSCs on T cell cycle
MSCs and MNCs were prepared as described before. T
cells, stimulated with PHA (50 g/ml, final concentration)
stimulation for 3 days, were cultured alone or cocul-
tured with MSCs (derived from normal and MDS
patient) or 3T3 cell line, then harvested and quantified.
One million T cells were fixed with 70% cold ethanol at
4°C for 30 min, washed with PBS twice, and stained
with 50 g/ml PI (Sigma, USA) at room temperature for
5 min. Data were analyzed with Mod-FIT software.
Effect of MSCs on T cell activation
MSCs and MNCs were prepared as described before,
respectively. T cells were cultured alone or cocultured
with prepared MSCs and stimulated with PHA (50 g/ml
final concentration). The expression of CD25 (BD, USA)
and CD69 (BD, USA) was detected by flow cytometry at
24 h, and CD44 (BD, USA) was detected at 72 h.
Effect of MSCs on T cell apoptosis
MSCs and MNCs were prepared as described before. T
cells were cultured alone or cocultured withMSCs with
PHA (50 g/ml final concentration) stimulation for 3
days, then harvested and quantified, stained with
Annexin-V kit (BD, USA), and analyzed by flow cytome-
try (FACS Vantage).
RNA-i experiments
The si-RNA sequence targeting human MMP-9 (from
mRNA sequence; Invitrogen online) corresponds to the
coding region 377-403 relative to the first nucleotide of
the start codon (target = 5’-AAC ATC ACC TAT TGG
ATC CAA ACT AC-3’). Computer analysis using the
software developed by Ambion Inc. confirmed this
sequence to be a good target. si-RNAs were 21 nucleo-
tides long with symmetric 2-nucleotide 3’overhangs
composed of 2’-deoxythymidine to enhance nuclease
resistance. The si-RNAs were synthesized chemically
and high pressure liquid chromatography purified (Gen-
set, Paris, France). Sense si-RNA sequence was 5’-CAU
CAC CUA UUG GAU CCA AdT dT-3’.A n t i s e n s es i -
RNA was 5’-UUG GAU CCA AUA GGU GAU GdT
dT-3’. For annealing of si-RNAs, mixture of comple-
mentary single stranded RNAs (at equimolar concentra-
tion) was incubated in annealing buffer (20 mM
Tris-HCl pH 7.5, 50 mM NaCl, and 10 mM MgCl2)f o r
2 minutes at 95°C followed by a slow cooling to room
temperature (at least 25°C) and then proceeded to
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cultured at 50% confluence in 6-well plates (10 cm
2)
were washed two times with OPTIMEM 1 (Invitrogen)
without FCS and incubated in 1.5 ml of this medium
without FCS for 1 hour. Then, cells were transfected
with MMP-9-RNA duplex formulated into Mirus Tran-
sIT-TKO transfection reagent (Mirus Corp, Interchim,
France) according to the manufacturer’s instructions.
Unless otherwise described, transfection used 20 nM
RNA duplex in 0.5 ml of transfection medium OPTI-
MEM 1 without FCS per 5 × 10
5 cells for 6 hours and
then the medium volume was adjusted to 1.5 ml per
well with RPMI 2% FCS. SilencerTM negative control 1
si-RNA (Ambion Inc.) was used as negative control
under similar conditions (20 nM). The efficiency of
silencing is 80% in our assay.
Enzyme-linked Immunoadsorbent Assays
This was carried out according to the manufacturer’s
recommendations (Oncogene Research Products).
Results were compared with those obtained with serially
diluted solutions of commercially purified controls.
Anti-human cytokine antibodies (R&D Systems, Min-
neapolis, MN) was added at 0.4 ug/ml in 0.05 M bicar-
bonate buffer (pH 9.3) to 96-well, U-bottom, polyvinyl
microplates (Becton Dickinson and Co., Oxnard, CA)
and the cell number was 1 × 10
5/100 ul. After incuba-
tion overnight at 4°C, the plates were washed and
blocked with 1% gelatin for 1 hour. Samples (50 ul) or
standard protein diluted in 0.5% gelatin were added to
the wells. After incubation for 1 hour at 37°C, the plates
were washed again, and 50 ng/ml biotinylated antimouse
antibody (R&D Systems) was added for 1 hour at 37°C.
The plates were then washed and incubated with strep-
tavidin-HRP for 1 hour at 37°C. After washing, 0.2 mM
ABTS (Sigma Chemical Co.) was added to the wells,
and after 10 minutes, the colorimetric reaction was mea-
sured at 405 nm with an ELISA reader VERSAmax
(Molecular Devices, Sunnyvale, CA).
Western blot
CML hemangioblasts were harvested at specific times
after treatment with regents as indicated in each experi-
ment. Cells were mixed with loading buffer and subject
to electrophoresis. After electrophoresis, proteins were
transferred to polyvinyl difluoride membranes (Pall Fil-
tron) using a semidry blotting apparatus (Pharmacia)
and probed with mouse mAbs, followed by incubation
with peroxidase-labeled secondary antibodies. Detection
was performed by the use of a chemiluminescence sys-
tem (Amersham) according to the manufacturer’s
instructions. Then membrane was striped with elution
buffer and reprobed with antibodies against the nonpho-
sphorylated protein as a measure of loading control.
Controls for the immnoprecipitation used the same pro-
cedure, except agarose beads contained only mouse IgG.
Statistics
Statistical analysis was performed with the statistical
SPSS 13.0 software. The paired-sample t-testwas used to
test the probability of significant differences between
samples. Statistical significance was defined as p < 0.05.
Results
The biological characteristics of CML hemangioblasts
To establish the characteristics of CML hemangioblasts,
we first examined the morphology, phenotype and
growth patterns of them respectively. Results showed
that they persistently displayed fibroblast-like morphol-
ogy (Figure 1A) and CML specific BCR/ABL oncogene
w a so b s e r v e db yF I S Ha n a l y s i s( F i g u r e1 B )a n dP C R
(Figure 1C) in CML hemangioblasts. Isotype analysis
indicated they were all persistently negative for CD34
and CD31 but positive for Flk1, CD29, CD44 and
CD105 (Figure 1D).
Immunomodulatory decrease on T cell proliferation
To analyse immunomodulatory effects on T cell prolif-
eration, irradiated MSCs were added to mitogen-stimu-
lated T cell proliferation reactions and mixed
lymphocyte reactions (MLR). A previous study showed
that MSCs from healthy volunteers could obviously inhi-
bit the proliferation of T cells not only stimulated with
mitogen but also in MLR. Additionally, this inhibitory
effect occurred in a dose-dependent manner. In mito-
gen-stimulated T cell proliferation assays, the prolifera-
tion of T cells at 1:2 ratio (MSCs to MNCs) was
significantly inhibited to about 1% with normal MSCs,
but proliferation at the same ratiowas inhibited only to
about 37% with CML-derived MSCs (compared with co-
culture system of normal MSCs, p < 0.05). Similarly,
inhibitory rates were impaired at 1:10 ratio (MSCs to
MNCs) in CML-derived MSCs (compared with co-cul-
ture system of normal MSCs, p < 0.05). Also the inhibi-
tory effect was dose dependent in CML-derived MSCs.
(Figure 2A). In MLR, a similar impaired inhibitory effect
with MDS-derived MSCs was observed. (Figure 2B)
Immunomodulatory attenuation of MSCs on T cell cycle
A previous study showed that MSCs could silence T
cells in G0/G1 phase, which might be one of the possi-
ble mechanisms of MSC’s inhibitory effect on T cells.
When the inhibitory effect of CML-derived MSC on T
cell proliferation was impaired, the related inhibitory
effect on cell cycle was analyzed. In a PHA-stimulating
system without MSC co-culture, there were 67.3 ± 3.7%
and 28.4 ± 2.9% T cells in G0/G1 phase and S phase,
respectively. When normal MSCs were present in co-
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phase were 94.0 ± 1.9% and 3.1 ± 1.9%, respectively
(compared with PHA stimulated T cells, p < 0.05).
MSCs from healthy volunteers could have most of their
T cells in G0/G1 phase with fewer cells entering S
phase. However, T cells in G0/G1 phase and S phase
remained 74.5 ± 1.2% and 22.1 ± 2.4% in the co-culture
system of CML-derived MSCs (compared with co-cul-
ture system of normal MSCs, p < 0.05). This result was
confirmed by five independent tests (Figure 3). The 3T3
cell line was used as a control, and no effects on cell
cycle were observed (70.3 ± 3.1% in G0/G1 and 27.3 ±
5.1% in S, respectively (compared with PHA stimulated
T cells, p > 0.05). These results suggested that the
Figure 1 Biological characteristics of the CML MSCs. (A) The morphology of hemangioblasts from CML (Magnification × 200). (B) BCR/ABL
fusion gene was detected by FISH (yellow signal is the positive one) in CML hemangioblasts from male patients. (C) BCR/ABL fusion gene was
detected by RT-PCR(line4,6,8,10 correspond to non-special amplification).(D) Isotype analysis showed they were all persistently negative for CD34
and CD31 but positive for Flk1, CD29, CD44 and CD105.
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arrest was also impaired.
Impaired effects of MSCs on T cell activation
MSCs from CML patients could significantly inhibit acti-
vation of T cells. The percentage of CD25, CD69 and
CD44 in PHA induced T lymphocyte was 12.3 ± 3.5%,
34.5 ± 5.9% and 29.4 ± 7.0% respectively. But they were
3.1 ± 2.3%, 6.4 ± 3.2% and 2.1 ± 1.7% when co-cultured
with normal hemangioblasts and, when co-cultured with
CML hemangioblasts, they were 5.4 ± 2.3%, 31.5 ± 6.8%
and 24.5 ± 3.6% respectively. All data presented here
were confirmed by repeated tests (Figure 4). These
results also indicated that MSCs from CML patients were
impaired in their immuno-modulatory function.
Dampening effect of MSCs on T cell apoptosis
In apoptosis tests, we have observed that MSCs from
healthy volunteers could significantly dampen the effect
of activation-induced apoptosis of T cells. Following sti-
mulation with PHA for 3 days, the rate of apoptosis of
T cells was 23.37 ± 2.71%. When PHA-stimulated T
c e l l sw e r ec o c u l t u r e dw i t hM S C so b t a i n e df r o mh e a l t h y
volunteers, the percentage of apoptotic T cells decreased
to 14.1 ± 0.65% (compared with PHA stimulated T cells,
p < 0.05). In the same condition, the apoptosis percen-
tage of T cells co-cultured with MDS-derived MSCs
further decreased to 8.36 ± 1.31% (compared with co-
culture systemof normalMSCs, p < 0.05). We repeated
the experiment five times to confirm this result (Figure
5). These results suggested the dampening effect of
CML-derived MSCs on activation-induced T apoptosis
seemed to be enhanced.
Efficient extinction of MMP-9 expression in HT1080 cells
by RNAi strategy and the concomitantly upregulation of
s-ICAM-1
We used an RNAi method to target MMP-9 in the
CML MSC and the constructs we designed encoded an
RNA that targets the MMP-9 mRNA. The target
sequence had no homology with other members of the
MMP family. The ds-RNA and Silencer negative control
si-RNA (snc) were each tested for their ability to sup-
press MMP-9 specifically. We first assessed whether
RNAi was dose and time-dependent. A MMP-9 depen-
dent ds-RNA-mediated inhibition was observed in a
dose and time dependent manner (Figure 6A). The
time-course assay performed with 20 nM ds-RNA-trans-
fected CML MSC showed that the induced MMP-9
silencing could be maintained for at least 3 days (Figure
Figure 3 Effects ofMSCs on T cell cycle. Flk-1+CD31-CD34- MSCs
or 3T3 at 1:10 ratios (MSCs to T cells); the data are expressed as
mean ± S.D. Of triplicates of five separate experiments with similar
results. Cell cycles of PHA-stimulated T cells were analyzed in T cells
alone (Ts), cocultured with MSCs (MSC + Ts) group andMSCs
derived from CML patient group (CML MSC + Ts). 3T3 cell line was
used as control (3T3 + Ts). Data are shown as means ± S.D. of five
independent experiments (*p ≥ 0.05, **p < 0.05 vs. Ts)
Figure 2 The effects of Flk-1+CD31-CD34- MSCs on T
lymphocyte proliferation. (A) The effects of Flk-1+CD31-CD34-
MSCs on T lymphocyte proliferation in mitogen proliferative assays.
There are three groups, including nonstimulated T cells (none), PHA-
stimulated T cells (Ts) and PHA-stimulated T cells cocultured with
MSC at different ratios (MSC to T cell = 1:2, 1:10, :100). Data are
shown as means ± S.D. of three independent experiments (*p <
0.05,**p < 0.005 vs. Ts). (B) The effects of Flk-1+CD31-CD34- MSCs
on T lymphocyte proliferation in MLR. Flk-1+CD31-CD34- MSCs at
1:10 ratios (irradiated MSCs to T cells); there are four groups,
including nonstimulated responder T cells (T0), irradiated stimulator
cells plus responder T cells; normalMSC plusMLR (BMSC Ts), CML-
derived MSC plus MLR (CML Ts). Data are shown as means ± S.D. of
three independent experiments (*p ≥ 0.05,**p = 0.001 vs. Ts)
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ging with MMP-9. The Western blotting results were
confirmed by enzyme-linked immunoadsorbent assay.
CML snc-RNA-transfected cells cultured up to 3 days
spontaneously released high amount of MMP-9 into the
culture conditioned medium whereas ds-RNA-trans-
fected cells showed a marked time- and dose- depen-
dent inhibition in MMP-9 protein levels. Importantly,
levels of s-ICAM-1 were also affected with ds-RNA
transfection (Figure 6C).
Discussion
MSC isolated from different tissues had immune regula-
tion ability not only in vivo but in vitro and it might
consist the “immune protection site” in human body
[25,26]. Considering their richness in source, availability
for expansion, and most importantly, their robust
immuno-modulatory activity, MSCs appear to be a
primary candidate for cellular therapy in immune disor-
ders[12,16,27]. In normal physiological conditions,
M S C sa r ev e r ys c a r c e( o n eM S Cp e r1 0 , 0 0 0 -
100,000MNC), therefore, normal immune responses
against foreign antigens are not affected. This is consis-
tent with in vitro results showing that immuno-suppres-
sive function was abolished when the ratio of MSC to T
cells was less than 1:100. However, once a large number
of MSCs were infused for immune therapy, influx of
MSC in the circulation and bone marrow could bring
the hypersensitive immune response to normal. More-
over, MSC infusion could not only modulate immune
responses but enhance the hematopoietic microenviron-
ment. Transplantation of MSCs offers bright prospects
in developing new therapies for blood diseases caused
by an abnormal immune system and impaired hemato-
poietic microenvironment. To date, MSCs have been
used to treat GVHD, which is a disorder of hyper-
immunoresponse, and shown to be effective clinically
[28,29].
Chronic myeloid leukemia is a clonal hematopoietic
stem cell disorder characterized by the t(9;22) chromo-
some translocation and resultant production of the con-
stitutively activated BCR/ABL tyrosine kinase[30].
Interestingly, this BCR/ABL fusion gene, was also
detected in the endothelial cells of patients with CML,
suggesting that CML might originate from hemangio-
blastic progenitor cells that can give rise to both blood
cells and endothelial cells. Although Interferon-a,
Figure 5 Effect of MSCs on T cell apoptosis. Flk-1+CD31-CD34-
MSCs at 1:10 ratios (MSCs to T cells); the data are expressed as
mean ± S.D. of triplicates of five separate experiments with similar
results. The test was conducted by Annexin-V and PI double
staining and analyzed by flow cytometry. Apoptosis of T cells was
analyzed in T cells alone (Ts), normalMSC cocultured with activated
T cells (MSC + Ts), and CML patient-derived MSC cocultured with
activatedT cells (CMLMSC + Ts). Annexin V+means the cells were PI
negative and Annexin V positive. Data are shown as means ± S.D.
of five independent experiments (*p < 0.05 vs. Ts).
Figure 4 Effects of Flk-1+CD31-CD34- MSCs on T lymphocyte
activation. Flk-1+CD31-CD34- MSCs at 1:10 ratios (MSCs to T cells);
the data are expressed as mean ± S.D. of triplicates of five separate
experiments with similar results. Activators of T cells were analyzed
including CD25, CD69, and CD44. The activation of T cells was
analyzed in T cells alone (Ts), normal MSC cocultured with activated
T cells (BMSC + Ts), and CML-derived MSC cocultured with activated
T cells (MDS MSC + Ts). Data are shown as means ± S.D. of five
independent experiments (*p ≥ 0.05,**p < 0.05 vs. Ts).
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cell transplantations are the standard therapeutic
options, transplant-related morbidity from graft-versus-
host disease and mortality rates of 10% to 20% have
greatly reduced the allogeneic hematopoietic cell trans-
plantation in clinics[31], while interferon-a is only effec-
tive in some patients to some degree and
chemotherapeutic intervention does not result in pro-
longed overall survival[32,33] and the reason is possibly
due to some unknown biology of the CML immune reg-
ulation[34].
We conducted this study of CML patient-derived
MSCs to evaluate the safety and effectiveness of autolo-
gous MSCs in treating CML. We tested the karyotype
and genetic changes of in vitro-expanded MSCs for
safety evaluation. The immuno-modulatory function of
MSCs was also examined. The investigation of CML
patient-derived MSCs could help to further elucidate
etiology and pathology of CML. Specifically, the answers
to questions of whether gene aberrations exist in MSCs
and whether the functions of MSCs are impaired are
crucial for understanding of CML development and
finding effective treatments.
We utilised Flk1+CD31-CD34- MSCs from CML
patients for 4-6 passages, and there were chromosomal
abnormities, indicating that mutation of CML happened
at the hematoangioblast level[35]. We thereby hypothe-
sized that malignant mutation existed in stem cells
more primordial than HSCs. Data from functional tests
proved that CML-derived MSCs had abnormal
immuno-modulatory function, although their MSCs
showed normal karyotype. An inhibitory effect on T cell
proliferation is an important characteristic of MSC in
immuno-modulatory action. A previous study, in accor-
dance with another report, suggested that the inhibitory
effect on T cell proliferation might be through cell cycle
arrest. MSCs from healthy volunteers could obviously
block T cells in G0/G1 phase. Int h i ss t u d y ,i n h i b i t o r y
effects of MDS-derived MSCs on T cell proliferation
were obviously impaired. Moreover, no significant cell
Figure 6 Efficient inhibition of MMP-9 in CML MSC using RNAi. (A) The cDNAs from snc-RNA (20 nM) and ds-RNA (1-20 nM) cells cultured
for up 3 days were used as templates for PCR reactions using specific primers for MMP-9 and ICAM-1. (B) The cDNAs from snc-RNA (20 nM) and
ds-RNA (20 nM) cells cultured for up 4 days were used as templates for PCR reactions using specific primers for MMP-9 or 18 S ribosomal RNA.
(C) MMP-9 and s-ICAM-1 production (ng/ml) in the culture supernatants of CML snc-RNA (20 nM) or ds-RNA (1-20 nM) cells were determined by
enzymelinked immunosorbent assays.
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Page 8 of 10cycle arrest was observed in PHA-stimulated T cells
cocultured with CML-derived MSCs. In addition, an
inhibitory effect on T cell activation is another key point
of immuno-modulatory function for MSCs, although
there are still disputes[21,22]. CD25, CD69 and CD44
are candidates for T cell activation in different phases.
In our study, MSCs from healthy volunteers showed sig-
nificant inhibitory effects on expression of T cell activa-
tion markers, but MSCs from CML patients showed
very limited inhibitory effects. These results suggested
that CML-derived MSCs have immunologic abnormal-
ities and their application in immuno-modulation might
be limited.
Normally, the invasion and metastasis by malignant
tumor cells consists of three major steps: the receptor-
mediated adhesion of tumor cells to the extracellular
matrix, the degradation of the extracellular matrix by
the proteinase secreted by the tumor cells, and the
transfer and proliferation of tumor cells[36]. So, the
loose of ECM and secreted cytokines are important for
the metastasis of the tumor cells from the primary
tumor[37]. Pathological conditions will change the
tumor cell fate leading to invasion and metastasis[38],
Local secretion of proteases have been implicated in this
tumor-stroma crosstalk. Matrix Metalloproteinase-9
(MMP-9) is one of them which has the preferential abil-
ity to degrade denatured collagens (gelatin) and collagen
type IV, the 2 main components of basement mem-
branes and therefore plays a critical role in tumour pro-
gression and metastaisis[39]. Moreover, its expression
increases with the increased or greater proliferation of
tumor cells.
We used a ds-RNA to interfere with the expression of
MMP-9 gene in CML MSC and our findings support
the conclusion that MMP-9 constitutes a trigger for the
switch between adhesive and invasive states in CML
MSC by changing the ICAM-1 from membrane-
anchored state to solvable one leading to tumor cell
immune evasion and metastasis.
In conclusion, the immune function of CML patient-
derived MSCs showed that their immuno-modulatory
ability, compared to MSCs from healthy volunteers, was
impaired, whichmight be a cause for an abnormal hema-
topoietic environment. This indicates that autologous
MSCs transplantation might be futile. Instead, allogenic
MSCs transplantation might b eab e t t e rc h o i c et oa m e -
liorate CML.
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